Abstract
Cardiovascular diseases are the major cause of non-communicable illness in both developing and developed nations, representing 30% of global deaths. New therapeutic approaches are desperately needed. Nanomedicine represents one such approach, and involves using molecular entities on the scale of 10-150 nanometers, for purposes of diagnosing, treating, and preventing disease. This review provides a basic overview of nanotechnology, then reviews specific applications of nanotechnology to cardiovascular diseases. Most research has focused on diagnosing and treating atherosclerosis using nanoparticles (NPs). However, researchers are beginning to study NPs for use in acute coronary syndromes, revascularization procedures, and heart failure. Antimicrobial NPs directed at biofilms likely have applicability to identifying and treating endocarditis. Despite the large disease burden of cardiovascular diseases, there are fewer researchers and less funding being applied to this research. Additional investment in NP therapies would pay great dividends once these therapies come of age.
Keywords: Nanotechnology, theranostics, cardiovascular diseases, atherosclerosis, acute coronary system.
Current Pharmaceutical Design
Title:Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Volume: 21 Issue: 42
Author(s): Patrick D Tyler and Peter M. Kang
Affiliation:
Keywords: Nanotechnology, theranostics, cardiovascular diseases, atherosclerosis, acute coronary system.
Abstract: Cardiovascular diseases are the major cause of non-communicable illness in both developing and developed nations, representing 30% of global deaths. New therapeutic approaches are desperately needed. Nanomedicine represents one such approach, and involves using molecular entities on the scale of 10-150 nanometers, for purposes of diagnosing, treating, and preventing disease. This review provides a basic overview of nanotechnology, then reviews specific applications of nanotechnology to cardiovascular diseases. Most research has focused on diagnosing and treating atherosclerosis using nanoparticles (NPs). However, researchers are beginning to study NPs for use in acute coronary syndromes, revascularization procedures, and heart failure. Antimicrobial NPs directed at biofilms likely have applicability to identifying and treating endocarditis. Despite the large disease burden of cardiovascular diseases, there are fewer researchers and less funding being applied to this research. Additional investment in NP therapies would pay great dividends once these therapies come of age.
Export Options
About this article
Cite this article as:
Tyler D Patrick and Kang M. Peter, Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases, Current Pharmaceutical Design 2015; 21 (42) . https://dx.doi.org/10.2174/1381612821666151027151957
DOI https://dx.doi.org/10.2174/1381612821666151027151957 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery Withdrawal Notice: Therapeutic Options for Treatment of COVID-19: A Review from Repurposed Drugs to New Drug Targets
Current Drug Targets Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Protein Preparation, Crystallization and Preliminary X-Ray Crystallographic Analysis of N-Acetylglutamate Kinase from Streptococcus mutans
Protein & Peptide Letters A Review of the English and Russian Language Literature on the Osteoarticular Manifestations of Brucellosis Infection
Current Rheumatology Reviews Biosynthesis and Genetic Engineering of Lipopeptide Antibiotics Related to Daptomycin
Current Topics in Medicinal Chemistry Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety Crystallization and Preliminary X-Ray Crystallographic Studies of SMU.134 Protein from Caries Pathogen Streptococcus mutans
Protein & Peptide Letters Heart Failure in South America
Current Cardiology Reviews The Family of Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Brucella as a Potential Agent of Bioterrorism
Recent Patents on Anti-Infective Drug Discovery Structural Insights into Chitinolytic Enzymes and Inhibition Mechanisms of Selective Inhibitors
Current Pharmaceutical Design Recent Advances in Natural Product-Based Anti-Biofilm Approaches to Control Infections
Mini-Reviews in Medicinal Chemistry Multiple Drugs Causing Severe Anemia in Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets 3-(1-Adamantylthio)-4-Phenylpyridine as a Potential Therapeutic for Methicillin-Resistant Staphylococcus aureus
Letters in Drug Design & Discovery Sutureless Aortic Valve Replacement Using Perceval S Valve
Recent Patents on Cardiovascular Drug Discovery